These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 33812443)

  • 41. Temozolomide as a Single Agent Maintenance Therapy in Elderly Patients With Primary CNS Lymphoma.
    Faivre G; Butler MJ; Le I; Brenner A
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):665-669. PubMed ID: 31351990
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Primary central nervous system lymphoma: Novel precision therapies.
    Mondello P; Mian M; Bertoni F
    Crit Rev Oncol Hematol; 2019 Sep; 141():139-145. PubMed ID: 31295667
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sustained response following BTK inhibitors based treatment in HIV-related primary central nervous system lymphoma: case report.
    Zhou Y; Wang X; Lin X; Wang J; Yan X; Wen Y
    AIDS Res Ther; 2023 Aug; 20(1):63. PubMed ID: 37644480
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Primary Central Nervous System Lymphomas.
    Chukwueke U; Grommes C; Nayak L
    Hematol Oncol Clin North Am; 2022 Feb; 36(1):147-159. PubMed ID: 34801161
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Primary central nervous system lymphoma: current state of anti-CD20 therapy and appraisal of reported response criteria.
    Siegal T
    J Clin Neurosci; 2014 May; 21(5):709-15. PubMed ID: 24725453
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse.
    Fossard G; Ferlay C; Nicolas-Virelizier E; Rey P; Ducray F; Jouanneau E; Faurie P; Belhabri A; Sunyack MP; Chassagne-Clément C; Thiesse P; Sebban C; Biron P; Blay JY; Ghesquières H
    Eur J Cancer; 2017 Feb; 72():12-19. PubMed ID: 28012348
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Diagnostic advances and new trends for the treatment of primary central nervous system lymphoma.
    Basso U; Brandes AA
    Eur J Cancer; 2002 Jul; 38(10):1298-312. PubMed ID: 12091059
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chemotherapy is effective as early treatment for primary central nervous system lymphoma.
    Boiardi A; Silvani A; Pozzi A; Fariselli L; Broggi G; Salmaggi A
    J Neurol; 1999 Jan; 246(1):31-7. PubMed ID: 9987711
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Lenalidomide, rituximab and dexamethasone for the treatment of recurrent/refractory or elderly newly diagnosed patients with primary central nervous system lymphoma: 5 cases report and literature review].
    Bai JF; Feng R; Han HX; Wang T; Li JT; Zhang CL; Liu H
    Zhonghua Xue Ye Xue Za Zhi; 2019 Dec; 40(12):1047-1049. PubMed ID: 32023740
    [No Abstract]   [Full Text] [Related]  

  • 50. High-dose Methotrexate plus temozolomide with or without rituximab in patients with untreated primary central nervous system lymphoma: A retrospective study from China.
    Chen C; Sun P; Cui J; Yan S; Chen H; Xia Y; Bi X; Liu P; Wang Y; Yang H; Nie M; Zhang XW; Jiang W; Li ZM
    Cancer Med; 2019 Apr; 8(4):1359-1367. PubMed ID: 30821418
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Treatment of Primary CNS Lymphoma: Maximizing Clinical Benefit, Minimizing Neurotoxicity.
    Song KW; Batchelor T
    Curr Oncol Rep; 2021 Sep; 23(11):132. PubMed ID: 34524547
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Primary central nervous system lymphoma: Retrospective analysis of 34 cases in a single centre.
    Wang H; Wang M; Wei J; Wang L; Mao L; Jin J
    J Int Med Res; 2018 Feb; 46(2):883-894. PubMed ID: 28984175
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival.
    Martinez-Calle N; Poynton E; Alchawaf A; Kassam S; Horan M; Rafferty M; Kelsey P; Scott G; Culligan DJ; Buckley H; Lim YJ; Ngu L; McCulloch R; Rowntree C; Wright J; McKay P; Fourali S; Eyre TA; Smith J; Osborne W; Yallop D; Linton K; Fox CP; Cwynarski K
    Br J Haematol; 2020 Aug; 190(3):394-404. PubMed ID: 32232989
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rituximab in primary central nervous system lymphoma-A systematic review and meta-analysis.
    Schmitt AM; Herbrand AK; Fox CP; Bakunina K; Bromberg JEC; Cwynarski K; Doorduijn JK; Ferreri AJM; Illerhaus G; Issa S; Schorb E; Zucca E; Hemkens LG; Schandelmaier S; Kasenda B
    Hematol Oncol; 2019 Dec; 37(5):548-557. PubMed ID: 31418878
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.
    Soussain C; Suzan F; Hoang-Xuan K; Cassoux N; Levy V; Azar N; Belanger C; Achour E; Ribrag V; Gerber S; Delattre JY; Leblond V
    J Clin Oncol; 2001 Feb; 19(3):742-9. PubMed ID: 11157026
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Primary central nervous system lymphoma: advances in treatment strategies].
    Kondo E
    Rinsho Ketsueki; 2020; 61(5):510-519. PubMed ID: 32507817
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma.
    Raizer JJ; Rademaker A; Evens AM; Rice L; Schwartz M; Chandler JP; Getch CC; Tellez C; Grimm SA
    Cancer; 2012 Aug; 118(15):3743-8. PubMed ID: 22179954
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma.
    Vu K; Mannis G; Hwang J; Geng H; Rubenstein JL
    Br J Haematol; 2019 Jul; 186(1):180-183. PubMed ID: 30714128
    [No Abstract]   [Full Text] [Related]  

  • 59. Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy.
    Qian L; Zhou C; Shen J; Cen J; Yin W
    Oncotarget; 2016 May; 7(18):25783-90. PubMed ID: 27029056
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Primary Central Nervous System Lymphoma: Evolving Biologic Insights and Recent Therapeutic Advances.
    Chihara D; Dunleavy K
    Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):73-79. PubMed ID: 33288483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.